Pharmacodynamics and clinical use of anti-HIV drugs

Infect Dis Clin North Am. 2003 Sep;17(3):651-74. doi: 10.1016/s0891-5520(03)00064-3.

Abstract

Antiretroviral drug exposure has been linked to both antiviral efficacy and the development of toxicity and further research in this area is ongoing and necessary. Use of these data may have important implications for TDM of HAART regimens in clinical practice. TDM, in conjunction with an assessment of the patient's viral resistance in the form of an IQ, needs to be examined and validated in large clinical trials.

Publication types

  • Review

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / physiology
  • Anti-HIV Agents* / pharmacokinetics
  • Anti-HIV Agents* / pharmacology
  • Anti-HIV Agents* / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • Area Under Curve
  • Biological Availability
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / administration & dosage
  • Half-Life
  • Humans
  • Protein Binding

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Anti-HIV Agents
  • HIV Protease Inhibitors